• Barthel Index [ Time Frame: Measured at weeks 1, 9, and 12 ] [ Designated as safety issue: Yes ]
• Leg motor Fugl-Meyer scale [ Time Frame: Measured at baseline and weeks 1, 2, 4, 6, 7, 8, 9, and 12 ] [ Designated as safety issue: Yes ]
• Stroke Impact Scale-16 [ Time Frame: Measured at weeks 1, 4, 7, 9, and 12 ] [ Designated as safety issue: Yes ]
• Gait endurance [ Time Frame: Measured at weeks 1, 2, 4, 6, 7, 8, 9, and 12 ] [ Designated as safety issue: Yes ]
• Hamilton Depression Scale [ Time Frame: Measured at baseline and weeks 1, 2, 9, and 12 ] [ Designated as safety issue: Yes ]
• Safety [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]

• Barthel Index
• Leg motor Fugl-Meyer scale
• Stroke Impact Scale-16
• Gait endurance
• Hamilton Depression Scale
• Safety

The purpose of this study is to assess efficacy, as well as safety, of Ropinirole in improving movement among patients with chronic stroke.

Stroke is a leading cause of disability. Current treatments target injury and must be delivered within hours. A body of literature suggests that there are processes ongoing days-months after stroke that can be targeted therapeutically, and improve function. The current study evaluates one such potential therapy, the dopamine agonist ropinirole. The current study tests the hypothesis that patients with chronic stroke randomized to ropinirole+physiotherapy will show improved gait velocity over the 12 weeks of study participation as compared to patients randomized to placebo+physiotherapy. A secondary aim is to test the hypothesis that ropinirole will improve three secondary endpoints at 12 weeks after study entry: the proportion of patients with no significant disability (Barthel Index ≥ 95); overall motor status, measured with the arm/leg FM score; and overall physical function, defined as the score on the Stroke Impact Scale-16 (SIS-16). This study will also evaluate the safety of ropinirole in patients recovering from stroke.

• Cerebrovascular Accident
• Hemiparesis

• Drug: Ropinirole (+ physical therapy)
• Drug: (vs.) Placebo + physical therapy

Inclusion Criteria:

1. Stroke onset 4 weeks-12 months prior
2. Stroke is radiologically confirmed as either (a) ischemic or (b) hemorrhagic
3. Minimum age 18
4. No significant pre-stroke disability
5. No other stroke in previous 3 months
6. Absence of major depression
7. Fugl-Meyer (FM) motor score of 23-83 out of 100
8. Functional Independence Measure (FIM) ambulation-subscore of 3 or more, and 50 foot walk takes longer than 15 seconds

Exclusion Criteria:

1. Significant daytime somnolence or any substantial decrease in alertness, language reception, or attention
2. Pregnant or lactating
3. Advanced liver, kidney, cardiac, or pulmonary disease
4. Orthostatic hypotension
5. Current use of ciprofloxacin, a centrally acting dopamine agonist, or a centrally active dopamine antagonist
6. A terminal medical diagnosis consistent with survival < 1 year
7. Coexistent major neurological disease
8. Coexistent major psychiatric disease
9. A history of significant alcohol or drug abuse in the prior 3 years
10. A coexistent disease characterized by an abnormality of CNS dopaminergic tone
11. Current enrollment in another investigational study related to stroke or stroke recovery
12. Contraindication to ropinirole prescription